Jinxin Fertility (JXR) AGM: FY2025 Accounts Adopted, HK$0.0418 Dividend Declared, Auditor Re-appointed

Bulletin Express
06/25

Jinxin Fertility Group Limited (JXR) reported that all resolutions tabled at the Annual General Meeting (AGM) on 25 June 2026 were approved by poll.

Key outcomes:

1. FY2025 financial statements and accompanying reports were adopted with 99.87% of votes cast in favour (252.63 million shares).

2. Board composition was confirmed: • Executive Director Dr. Geng Lihong re-elected (99.07% approval). • Non-executive Director Ms. Yan Xiaoqing re-elected with the same support level. • Independent Non-executive Directors Dr. Chong Yat Keung and Mr. Wang Xiaobo secured 99.56% and 99.56% support respectively.

3. The Board was authorised to set directors’ remuneration, receiving 99.57% approval.

4. A final dividend of HK$0.0418 per share for FY2025 was approved with 99.99% support, clearing the way for cash distribution to shareholders.

5. Deloitte Touche Tohmatsu was re-appointed as external auditor until the next AGM, supported by 80.17% of votes (202.79 million shares), while 19.83% voted against.

6. Capital mandates: • General issuance mandate for up to 20% of issued shares passed with 59.39% approval. • Share repurchase mandate for up to 10% of issued shares was strongly backed with 99.99% approval. • Extension of the issuance mandate by the amount of shares repurchased also attained 59.39% support.

Voting base and scrutineer: Of the 2.71 billion shares in issue, 79.92 million repurchased shares pending cancellation were excluded, leaving 2.57 billion shares eligible to vote. Computershare Hong Kong Investor Services acted as scrutineer.

All ordinary resolutions required a simple majority and were duly passed, solidifying board continuity, confirming the dividend, renewing the auditor and providing the board with refreshed capital management flexibility.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10